Allergic rhinitis affects between 15% and 20% of the population in the seven major markets. Currently available treatments focus on symptom relief; however, a significant number of allergic rhinitis patients with uncontrolled symptoms remain. Shorter, safer, and more convenient therapies currently in development may lead to a substantial market expansion.

• Detailed break-down of the prevalence of allergic rhinitis by country, severity and type of allergen
• Evaluation of current strategies for the treatment of this disease, including the current role of immunotherapy
• Analysis of future trends in immunotherapy
• Assessment of the potential for new immunotherapies


Highlights



The prevalence of allergic rhinitis in the seven major markets ranges from 7.9% (Spain) to 17.2% (France), but only about half of the affected population currently seek treatment.





Immunotherapy is dominated by a few regional players, constituting a small niche within the EUR 16 billion allergic rhinitis market.





Several small companies are developing immunotherapy products with likely competitive advantages over currently available products. The aim is to achieve shorter sublingual immunotherapy courses.



Reasons to Purchase


• Identify the most lucrative targets for immunotherapeutic product development strategies in allergic rhinitis
• Detailed breakdown of the prevalence of allergic rhinitis according to country, severity and allergen
• Gain competitive advantages when positioning new immunotherapies for allergic rhinitis